Shop Apotheke Europe N.V. re-confirmed earnings guidance for 2022. For the full-year 2022, the Management Board expects to grow everything-but-Rx (non-Rx) sales by double-digits in the range of 15 to 25%.
Market Closed -
Other stock markets
|
After market 01:07:36 pm | |||
130 EUR | 0.00% | 131.2 | +0.88% |
03:22pm | REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating | ZD |
02:13pm | REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating | ZD |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.22% | 2.81B | |
-31.97% | 10.1B | |
+8.14% | 6.12B | |
-11.41% | 5.97B | |
-30.42% | 5.65B | |
-0.88% | 4.71B | |
+51.58% | 4.26B | |
-12.22% | 3.58B | |
-14.86% | 3.26B | |
-6.93% | 3.07B |
- Stock Market
- Equities
- RDC Stock
- News Redcare Pharmacy NV
- Shop Apotheke Europe N.V. Re-Confirms Earnings Guidance for 2022